Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India (SII), on Monday, announced a regulatory submission to the South African Health Products Regulatory Agency (SAHPRA) for emergency use authorization (EUA) of Novavax recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.
Novavax and Serum Institute of India (SII) announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization (EUA) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine